| John Grimes, CRNP | |
|
7938 Al Hwy 69, Suite 100, Guntersville, AL 35976 | |
| (256) 571-8445 | |
| (256) 571-8447 |
| Full Name | John Grimes |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 7938 Al Hwy 69, Guntersville, Alabama |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174956908 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2100X | Nurse Practitioner - Acute Care | 1-083810 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Marshall Medical Centers | Boaz, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Marshall Medical Center South Manganaris Pulmonology | 5092976787 | 6 |
News Archive
A trial involving an edible sensor connected to a paired mobile, that enables medical staff to remotely see patients` intake of tuberculosis (TB) medicine, has produced superior results to directly observed therapy (DOT), where a healthcare worker watches the patient swallow medication, leading researchers to suggest that the technology could be a game changer in high prevalence countries where treatment adherence remains a stumbling block to eliminating TB.
DiagnoCure Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that it signed an exclusive agreement with a new partner, Lab21, a global provider of diagnostic products and services, for the promotion, marketing and selling of its Previstage(TM) GCC Colorectal Cancer Staging Test in the United Kingdom and Ireland.
Applied NeuroSolutions, Inc.(www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today confirmed, as previously disclosed in July 2009, that it has achieved sufficient analytical sensitivity to detect tau in serum patient samples.
Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
› Verified 9 days ago
| Entity Name | Marshall Medical Center South Manganaris Pulmonology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013299304 PECOS PAC ID: 5092976787 Enrollment ID: O20120405000090 |
News Archive
A trial involving an edible sensor connected to a paired mobile, that enables medical staff to remotely see patients` intake of tuberculosis (TB) medicine, has produced superior results to directly observed therapy (DOT), where a healthcare worker watches the patient swallow medication, leading researchers to suggest that the technology could be a game changer in high prevalence countries where treatment adherence remains a stumbling block to eliminating TB.
DiagnoCure Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that it signed an exclusive agreement with a new partner, Lab21, a global provider of diagnostic products and services, for the promotion, marketing and selling of its Previstage(TM) GCC Colorectal Cancer Staging Test in the United Kingdom and Ireland.
Applied NeuroSolutions, Inc.(www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today confirmed, as previously disclosed in July 2009, that it has achieved sufficient analytical sensitivity to detect tau in serum patient samples.
Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Grimes, CRNP 211 Ohara Dr, Apt/suite, Albertville, AL 35950-2597 Ph: (256) 293-8141 | John Grimes, CRNP 7938 Al Hwy 69, Suite 100, Guntersville, AL 35976 Ph: (256) 571-8445 |
News Archive
A trial involving an edible sensor connected to a paired mobile, that enables medical staff to remotely see patients` intake of tuberculosis (TB) medicine, has produced superior results to directly observed therapy (DOT), where a healthcare worker watches the patient swallow medication, leading researchers to suggest that the technology could be a game changer in high prevalence countries where treatment adherence remains a stumbling block to eliminating TB.
DiagnoCure Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that it signed an exclusive agreement with a new partner, Lab21, a global provider of diagnostic products and services, for the promotion, marketing and selling of its Previstage(TM) GCC Colorectal Cancer Staging Test in the United Kingdom and Ireland.
Applied NeuroSolutions, Inc.(www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today confirmed, as previously disclosed in July 2009, that it has achieved sufficient analytical sensitivity to detect tau in serum patient samples.
Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
› Verified 9 days ago
Hollie Lane Sims, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 38 Rowe Dr, Guntersville, AL 35976 Phone: 256-571-8460 | |
Miss Jennifer Lynn Sanders, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: Marshall Medical Center North, 8000 Alabama Hwy 69, Guntersville, AL 35976 Phone: 256-571-8108 | |
Mr. John Paul Mizelle, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2017 Obrig Ave, Guntersville, AL 35976 Phone: 256-582-2324 | |
Mrs. Jessica Wallace Howard, MSN, AGNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 55 Rowe Dr, Suite C, Guntersville, AL 35976 Phone: 256-571-8807 | |
Katie Giles, WHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 55 Rowe Dr Ste A, Guntersville, AL 35976 Phone: 256-571-8470 Fax: 256-571-8474 | |
Cathy Dawn Eubanks, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1241 Blount Ave, Guntersville, AL 35976 Phone: 256-582-6377 Fax: 256-582-6377 |